Shang Hai Zheng Quan Bao·2026-02-27 20:54Core Viewpoint - Rongchang Biopharmaceutical (Yantai) Co., Ltd. has announced a change in its signing registered accountant for the 2025 fiscal year, with the appointment of Zhu Wenyang to replace Wang Min, who has resigned [2][6]. Group 1: Change of Signing Registered Accountant - The company has reappointed Ernst & Young Huaming as its domestic audit firm and Ernst & Young as its overseas audit firm for the 2025 fiscal year [2]. - Zhu Wenyang, who became a registered accountant in 2022 and has been with Ernst & Young Huaming since 2021, will now serve as the signing accountant alongside Yang Jing [3][6]. Group 2: Financial Performance Overview - For the fiscal year 2025, the company reported a revenue of RMB 325,105.11 million, representing a year-on-year increase of 89.36% [10]. - The net profit attributable to the parent company reached RMB 70,852.33 million, with a significant improvement in profitability due to increased sales of core products and successful collaborations [10][11]. - Total assets grew by 31.65% to RMB 723,868.50 million, while equity attributable to the parent company increased by 81.40% to RMB 360,304.78 million [10][12]. Group 3: Factors Influencing Financial Performance - The increase in revenue was primarily driven by higher sales of the injectable drugs Tai'ta Xip and Vidi Xitomab, as well as substantial technology licensing income from Vor Biopharma Inc. [11]. - The company has improved its profitability through cost management and a reduction in sales expense ratios, leading to a significant enhancement in profit margins [10][11].